Pulmonary delivery nanomedicines towards circumventing physiological barriers: Strategies and characterization approaches

Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy

“…One of the challenges is that orthotropic lung cancer murine model is not easily established and the tumor growth is not intuitively monitored like the widely used subcutaneous tumor model. Other attentions should be paid to bypassing the physiological barriers in pulmonary delivery 243 and targeting cancerous but not healthy lung tissues. Second, combinational therapy offers a promising means to improve the antitumor effect and postpone/reverse drug resistance.…”

Rapamycin-based inhaled therapy for potential treatment of COPD-related inflammation: production and characterization of aerosolizable nano into micro (NiM) particles

“…1 On the other hand, nanomedicines are very promising in localized lung disease treatments via the design of appropriate carriers to allow mucus penetration, macrophagic escape/uptake and pulmonary surfactant corona inhibition, such as through size control and charge tuning, surface modification, co-delivery of mucolytic agents, and decoration with surface ligands. 2 In several pulmonary pathologies, macrophages show a defective phagocytosis capacity although they are increased in number; 3 therefore, they represent the optimal therapeutic target for the treatment of inflammatory respiratory diseases such as chronic obstructive pulmonary disease (COPD). 4,5 Because mannose receptors are highly expressed on alveolar macrophages, it has been widely demonstrated that mannosesurface decoration of nanocarriers is an active drug-targeting strategy to treat tumorigenesis, inflammation, and infections in lung diseases.…”

“…1 On the other hand, nanomedicines are very promising in localized lung disease treatments via the design of appropriate carriers to allow mucus penetration, macrophagic escape/uptake and pulmonary surfactant corona inhibition, such as through size control and charge tuning, surface modification, co-delivery of mucolytic agents, and decoration with surface ligands. 2…”

Nanomedicines for targeted pulmonary delivery: receptor-mediated strategy and alternatives

“…To date, numerous reviews have been published, summarizing the development of PDNs, which focused on diseases, [17][18][19] nanomaterials, [20][21][22] APIs 18,23 and physiologic barriers. 1 However, despite their promising role in the treatment and management of lung diseases, PDNs have several shortcomings. Importantly, PDNs often lack the specificity required for the targeted delivery of therapeutic agents.…”